The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $14.67

Today's change0.00 0.00%
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $14.67

Today's change0.00 0.00%
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.

Ironwood Pharmaceuticals Inc closed at (U.S.)$14.67.

Over the last five days, shares are unchanged, but have gained 26.36% over the last year to date. This security has outperformed the S&P 500 by 24.34% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $14.67
  • High--
  • Low--
  • Bid / Ask(U.S.) $0.01 / (U.S.) $2.00K
  • YTD % change+26.36%
  • Volume0
  • Average volume (10-day)790,151
  • Average volume (1-month)733,186
  • Average volume (3-month)1,013,926
  • 52-week range(U.S.) $9.01 to (U.S.) $15.95
  • Beta1.46
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.55
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-470.01%

Ironwood Pharmaceuticals Inc has a net profit margin of -470.01%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue177155
Total other revenue--------
Total revenue177155
Gross profit17-4134
Total cost of revenue01121
Total operating expense54625952
Selling / general / administrative29293029
Research & development25222723
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-37-55-44-47
Interest income (expense), net non-operating-5-5-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-42-60-50-52
Income after tax-42-60-50-52
Income tax, total0000
Net income-42-60-50-52
Total adjustments to net income--------
Net income before extra. items-42-60-50-52
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-42-60-50-52
Inc. avail. to common incl. extra. items-42-60-50-52
Diluted net income-42-60-50-52
Dilution adjustment0000
Diluted weighted average shares139138130121
Diluted EPS excluding extraordinary itemsvalue per share-0.30-0.44-0.38-0.43
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.30-0.44-0.38-0.43